טוען...
Gut microbiome and CAR-T therapy
Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly being evaluated in a variety of tumors in the relapsed/refractory as well as frontline disease...
שמור ב:
| הוצא לאור ב: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6862813/ https://ncbi.nlm.nih.gov/pubmed/31827982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0155-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|